Poseida Therapeutics Inc Ordinary Shares PSTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024
-
Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients
-
Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma
-
Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting
-
Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma
-
Poseida Therapeutics to Present at Upcoming Investor Conferences
-
Poseida Rises After Reporting Smaller-Than-Seen Loss, Partnership Progress
-
Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024
Trading Information
- Previous Close Price
- $2.54
- Day Range
- $2.52–2.64
- 52-Week Range
- $1.83–4.27
- Bid/Ask
- $2.63 / $2.68
- Market Cap
- $253.52 Mil
- Volume/Avg
- 523,986 / 454,828
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.81
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 337
- Website
- https://www.poseida.com
Comparables
Valuation
Metric
|
PSTX
|
CCCC
|
ARTV
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.17 | 1.50 | — |
Price/Sales | 2.81 | 10.88 | 4.39 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
PSTX
|
CCCC
|
ARTV
|
---|---|---|---|
Quick Ratio | 2.44 | 4.89 | 4.43 |
Current Ratio | 2.48 | 5.09 | 4.59 |
Interest Coverage | −11.50 | −715.67 | — |
Quick Ratio
PSTX
CCCC
ARTV
Profitability
Metric
|
PSTX
|
CCCC
|
ARTV
|
---|---|---|---|
Return on Assets (Normalized) | −33.29% | −22.53% | −16.21% |
Return on Equity (Normalized) | −92.95% | −34.97% | — |
Return on Invested Capital (Normalized) | −46.70% | −30.08% | — |
Return on Assets
PSTX
CCCC
ARTV
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk AS ADR
NVO
| Qqlwpllw | Xzs | $512.4 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Hjhqxyyh | Cnhpxr | $117.5 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Rdwcjcpl | Vcfhrtb | $111.6 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Pcxgscxv | Qlbwxh | $34.4 Bil | |||
argenx SE ADR
ARGX
| Xbqkjvs | Ykw | $31.7 Bil | |||
BioNTech SE ADR
BNTX
| Ljkqsfwyq | Wbyh | $29.2 Bil | |||
Moderna Inc
MRNA
| Vknwmkc | Ytdzw | $23.1 Bil | |||
United Therapeutics Corp
UTHR
| Vzxcvwhnm | Hdrh | $15.8 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Vphqyjt | Rpscvb | $13.2 Bil | |||
Incyte Corp
INCY
| Sqqgjjsv | Wggvdl | $13.0 Bil |